. Author manuscript; available in PMC: 2015 Dec 8.

Published in final edited form as: J Appl Stat. 2014 Jun 9;41(12):2676–2695. doi: 10.1080/02664763.2014.925102

Table 3.

Patient-specific meta-analysis risk estimates for hypothetical node-negative patients of age 50 with moderately differentiated tumors treated with tamoxifen or anastrozole.

Tumor size (cm)	RS	Tamoxifen		Anastrozole
Tumor size (cm)	RS	Risk estimate	95% CI	Risk estimate	95% CI
0.5	9	4.1%	(2.7%, 6.1%)	3.6%	(2.3%, 5.8%)
	24	8.5%	(6.1%, 11.8%)	7.5%	(5.0%, 11.4%)
	40	11.8%	(8.4%, 16.5%)	10.6%	(6.9%, 16.0%)
2	9	7.2%	(5.0%, 10.3%)	6.4%	(4.2%, 9.8%)
	24	14.5%	(11.1%, 18.9%)	13.0%	(8.9%, 18.7%)
	40	19.8%	(15.1%, 25.8%)	17.8%	(12.2%, 25.5%)
4	9	14.8%	(9.8%, 21.9%)	13.2%	(8.2%, 20.8%)
	24	27.1%	(19.7%, 36.5%)	24.4%	(16.3%, 35.6%)
	40	35.5%	(26.2%, 47.0%)	32.2%	(21.8%, 46.0%)